BioMedica Diagnostics


For quantitative determination of human urokinase-type plasminogen activator (uPA) and human plasminogen activator inhibitor type 1 (PAI-1) in tumor tissue extracts.
uPA and PAI-1 are important biomarkers which plays an important role in cell proliferation, invasion and metastasis of various cancers.
The measurement of both uPA and PAI-1 levels is a clinically validated diagnostic tool. It has achieved the highest level of evidence (LOE-1) for predicting the risk of relapse and response to adjuvant therapy in breast cancer patients.



The FEMTELLE uPA/PAI-1 ELISA Test assess the likelihood of breast cancer reappearance in women with newly diagnosed, node-negative breast cancer. The test has been validated in multiple independent long-term clinical studies with more than 8000 patients.

» FEMTELLE allows to identify patients with high (uPA and/or PAI-1 high) and low (uPA and PAI-1 low) risk of recurrence.
» uPA und PAI-1 are the only new prognostic factors which are recommended at the highest level of evidence (LOE-1) for therapy decision in node-negative breast cancer by the German Guidelines for Diagnosis and Treatment of breast cancer.
» The test system is suitable for routine testing and clinical use.
» Its high reproducibility has been demonstrated in the prospective evaluation of an International Quality Assurance program.

Additional information


96 tests per kit

You may also like…